{
  "items": "9",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Assessing YD Bio (YDES) Valuation After a Sharp One-Month Share Price Rebound",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ydes/yd-bio/news/assessing-yd-bio-ydes-valuation-after-a-sharp-one-month-shar",
      "time_published": "20251211T190917",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "YD Bio (YDES) has seen a significant 43% rebound in its share price over the past month, contrasting with a deeply negative three-month performance. The company's valuation, marked by an extremely high price-to-book ratio of 134.2x compared to an industry average of 2.8x, suggests investors are betting heavily on its future pipeline and growth potential. This optimistic outlook leaves little room for error given the inherent risks in biotech, such as clinical trial setbacks or funding issues.",
      "banner_image": "NULL",
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.938307"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.837522"
        }
      ],
      "overall_sentiment_score": -0.523077,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "YDES",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.513920",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Assessing YD Bio (YDES) Valuation After a Sharp One-Month Share Price Rebound",
      "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ydes/yd-bio/news/assessing-yd-bio-ydes-valuation-after-a-sharp-one-month-shar/amp",
      "time_published": "20251211T030910",
      "authors": [
        "Simply Wall St"
      ],
      "summary": "YD Bio (YDES) has seen a 43% share price rebound over the past month, partially recovering from earlier declines, though its P/B ratio of 134.2x suggests a very rich valuation compared to the industry average of 2.8x. This premium reflects high investor optimism about its pipeline and growth potential, implying that positive clinical trial outcomes and funding stability are crucial to justify its current price. Investors are advised to consider the risks associated with this optimistic valuation.",
      "banner_image": null,
      "source": "Simply Wall Street",
      "category_within_source": "General",
      "source_domain": "Simply Wall Street",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.905048"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.840585"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.733461"
        }
      ],
      "overall_sentiment_score": -0.409718,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "YDES",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.433751",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "YD Bio stock rises after FDA clearance for eye care products",
      "url": "https://www.investing.com/news/stock-market-news/yd-bio-stock-rises-after-fda-clearance-for-eye-care-products-93CH-4375674",
      "time_published": "20251124T123300",
      "authors": [
        "Investing.com"
      ],
      "summary": "YD Bio Ltd (NASDAQ:YDES) saw its stock rise by 5.3% after announcing regulatory milestones for its eye care products in the U.S. The company's Exovisse Contact Lenses received FDA 510(k) clearance, and Exovisse Artificial Tears are cleared for OTC distribution. These achievements mark YD Bio's entry into the U.S. eye care market, complementing ongoing clinical development for serious eye conditions.",
      "banner_image": "https://i-invdn-com.investing.com/news/LYNXNPEB7Q0U9_L.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.912857"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.700473"
        }
      ],
      "overall_sentiment_score": 0.844582,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "YDES",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.845505",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "YD Bio (Nasdaq: YDES) Wins FDA 510(k) for Exovisse Lenses, OTC Path for Tears",
      "url": "https://www.stocktitan.net/news/YDES/yd-bio-limited-announces-u-s-ophthalmology-market-entry-advances-4ng5si6f3mdm.html",
      "time_published": "20251124T050303",
      "authors": [
        "NULL"
      ],
      "summary": "YD Bio (Nasdaq: YDES) has achieved significant regulatory milestones for its ophthalmology products in the U.S. The company received FDA 510(k) clearance for its Exovisse Contact Lenses and developed Exovisse Artificial Tears in compliance with FDA OTC guidelines, enabling nationwide marketing. Additionally, YD Bio enrolled its limbal stem cells and LSC-derived exosomes in an FDA Drug Master File, establishing a regulatory pathway for future therapeutic developments.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.916887"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.627592"
        }
      ],
      "overall_sentiment_score": 0.441325,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "YDES",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.401377",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "YD Bio and EG BioMed Expand U.S. Access to OkaiDx\u2122, a cfDNA\u2011Methylation Blood Test for Post\u2011Treatment Breast Cancer Monitoring",
      "url": "https://finance.yahoo.com/news/yd-bio-eg-biomed-expand-133000998.html",
      "time_published": "20251109T200948",
      "authors": [
        "NULL"
      ],
      "summary": "YD Bio and EG BioMed have partnered to expand U.S. access to OkaiDx\u2122, a cfDNA-methylation blood test designed for research-use-only in post-treatment breast cancer monitoring. The test, which has demonstrated high accuracy, sensitivity, and specificity, is now available through EG BioMed's CLIA/CAP-certified laboratory in the United States. YD Bio will support commercialization, researcher engagement, and logistics to enable further study of post-treatment monitoring approaches.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.944574"
        }
      ],
      "overall_sentiment_score": 0.404414,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "YDES",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.432603",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "YDES Stock Price and Chart \u2014 NASDAQ:YDES",
      "url": "https://www.tradingview.com/symbols/NASDAQ-YDES/",
      "time_published": "20251023T050229",
      "authors": [],
      "summary": "This page provides a detailed overview of YD Bio Limited (YDES) stock on NASDAQ, including its current price, market capitalization, key financial statistics, and performance metrics. It also offers company details such as its sector, industry, CEO, and a brief description of its operations, alongside frequently asked questions about its stock.",
      "banner_image": null,
      "source": "TradingView",
      "category_within_source": "General",
      "source_domain": "TradingView",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.907037"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.812530"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.726843"
        },
        {
          "topic": "finance",
          "relevance_score": "0.628988"
        }
      ],
      "overall_sentiment_score": 0.025558,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "YDES",
          "relevance_score": "0.316188",
          "ticker_sentiment_score": "0.021837",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "YD Bio Limited Reports Unaudited Half Year 2025 Financial Results",
      "url": "https://www.globenewswire.com/news-release/2025/09/30/3159111/0/en/YD-Bio-Limited-Reports-Unaudited-Half-Year-2025-Financial-Results.html",
      "time_published": "20250930T172500",
      "authors": [
        "NULL"
      ],
      "summary": "YD Bio Limited announced its unaudited financial results for the six months ended June 30, 2025, highlighting its transition to a publicly traded biotech platform following a business combination and a $13.2 million private investment. The company reported a slight decrease in net revenue but increased investments in R&D and general and administrative functions to advance its cancer detection technology and ophthalmologic innovations. YD Bio is positioned to capture shares in oncology diagnostics, ocular therapeutics, and clinical-trial services markets, aiming for sustainable growth and long-term value creation.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/120c17d5-350b-43ba-93a7-43125065742d/image1.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.936976"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.823588"
        }
      ],
      "overall_sentiment_score": 0.238315,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "YDES",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.237718",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "$13.2M Funding Boost: YD Bio Advances DNA Methylation Cancer Tests and Eye Therapies Pipeline",
      "url": "https://www.stocktitan.net/news/YDES/yd-bio-limited-reports-unaudited-half-year-2025-financial-e8np8oauutek.html",
      "time_published": "20250930T050303",
      "authors": [],
      "summary": "YD Bio Limited reported its H1 2025 financial results, with net revenue decreasing by 9% to $204,007 and a significant net loss of $1.9 million due to increased operating expenses. Despite financial headwinds, the company secured $13.2 million in PIPE financing, became publicly traded, and is advancing its DNA methylation-based cancer detection technology and ophthalmologic innovations. Key developments include the launch of a pancreatic cancer screening LDT, plans for a breast cancer recurrence monitoring LDT, and the development of corneal stem-cell and exosome-based treatments for eye conditions with clinical trials expected in 2027.",
      "banner_image": "https://ml.globenewswire.com/media/MjM5YjdjNjMtYzk5MS00NzAwLTllYTctOTFmNjg2MDJkODhmLTUwMDE1MjY3MC0yMDI1LTA5LTMwLWVu/tiny/YD-Bio-Limited.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.931991"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.938308"
        }
      ],
      "overall_sentiment_score": 0.080836,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "YDES",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.052012",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "YD Bio Limited Announces Closing of Business Combination",
      "url": "https://www.citybiz.co/article/738076/yd-bio-limited-announces-closing-of-business-combination/",
      "time_published": "20250901T201005",
      "authors": [],
      "summary": "YD Bio Limited (Nasdaq: YDES) has completed its business combination with Breeze Holdings Acquisition Corp., with its shares and warrants now trading on Nasdaq. The transaction, approved by Breeze shareholders on August 14, 2025, along with a PIPE offering, is expected to provide over $11.5 million for future operations. This move positions YD Bio as an emerging leader in biotechnology, focused on advancing DNA methylation-based cancer detection and ophthalmologic innovations through strategic partnerships.",
      "banner_image": "https://www.citybiz.co/wp-content/uploads/2025/09/ydbio.jpg",
      "source": "citybiz",
      "category_within_source": "General",
      "source_domain": "citybiz",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.901788"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.933155"
        },
        {
          "topic": "finance",
          "relevance_score": "0.615195"
        }
      ],
      "overall_sentiment_score": 0.810198,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "YDES",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.849148",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}